Objective: To assess the clinical spectrum, treatment, and outcome of children with autoimmune encephalitis (AE). Study Design: Descriptive study. Place and Duration of the Study: Department of Paediatrics, The Aga Khan University Hospital, Karachi, Pakistan, from January 2017 to December 2021. Methodology: Medical records of children with a diagnosis of AE were reviewed for clinical features, treatment details, and outcomes. Outcome was de ned as good (0-2) or poor (3-6) based on a modi ed Rankin Scale (mRS) score at 3-month follow-up. Descriptive statistics were reported and logistic regression was used to assess the prognostic factors associated with outcome. Results: Thirty-three patients were identi ed with AE. Thirteen (39.3%) were antibody positive. Anti-N-methyl-D-aspartatreeceptor (NMDAR) antibody was seen in 92% of positive cases. Behavioural abnormalities (87.8%), seizures (81.8%), movement disorders (66.6%), psychiatric symptoms (63.6%), and mutism (33.3%) were the prominent symptoms. Thirty (91%) patients received rst-line immunotherapy. Good outcome was seen in 14 (48.2%) patients. Univariable analysis showed that the odds of having poor outcome were 2.5 (95% con dence interval [CI]0.37-16.88, p=0.34) in patients with chorea. In addition, an elevated cerebrospinal uid (CSF) protein had an odds ratio (OR) of 8.6 (CI 0.88-84.83, p=0.064) and positive CSF antibodies had an OR of 3.7 (CI 0.79-17.72, p=0.095) for a poor outcome. Mortality was seen in 4 (12.1%) patients. Conclusion: A very low threshold is needed for the diagnosis of AE in children presenting with behavioural symptoms and chorea. Although the odds for poor prognosis were higher in patients with chorea, elevated CSF protein and positive CSF antibodies, the pvalue did not come out signi cant.